Aion Therapeutic Company Information
|Name||Aion Therapeutic Inc|
|Industry||Drug Manufacturers—Specialty & Generic|
|Headquarters||45 Sheppard Avenue E., Ste 703|
Toronto, ON. M2N 5W9
Formerly known as Osoyoos Cannabis Inc, Aion Therapeutics is a pharmaceutical company that focuses on creating numerous patent-protected cannabis-mushroom compounds therapeutic formulations. The company brokered an agreement with a private Canadian legalized cannabis producer that offers extraction services to third-party establishments.
Aion Therapeutics Inc aims to utilize artificial intelligence to unlock medical cannabis and medical mushrooms’ healing power. Using these compounds, Aion intends to develop new treatments that will revolutionize the global healthcare system.
Similar to how mushrooms and cannabis plants grow together, forming a symbiotic relationship, Aion believes that they can work together to offer patients numerous therapeutic benefits.
The company is conveniently positioned in Jamaica, where medicinal mushrooms and medical cannabis are federally legal and regulated.
Aion Therapeutics and Artificial Intelligence
Using Artificial Intelligence, Aion Therapeutics Inc processes and analyzes the various compounds found on cannabis and mushroom plants. Afterward, they use AI technology to develop cannabis-mushroom treatments that offer patients specialized treatment. How?
Using AI technology, the company can examine an individual’s genomic information, classify the genome in relation to their unique characteristic, and then offer the patient therapeutic formulations specifically designed to suit their medical needs.
In summary, the company derives compounds with therapeutic potential from medicinal mushrooms and medical cannabis. It then combines them to create pharmaceuticals, cosmeceuticals, and nutraceuticals that contain therapeutic benefits for conditions like:
- Psychosis or psychotic disorders
- Weight loss for obese individuals
Aion Therapeutics’ mission
The company believes in Artificial Intelligence’s power in making life better and easier for everyone, especially in the medical industry. As a result, they have integrated the technology in their quest of finding the right cannabis-mushroom compounds to treat a myriad of conditions.
Currently, the company has completed the initial stages of drug formulation, nanotechnology, and laboratory testing. Product manufacturing is in process for all the compounds used to treat cancer, psychiatric disorders, antiviral, obesity, and inflammation disorders.
Clinical studies will be starting soon, and afterward, if all goes well, they will begin the commercial production of pharmaceuticals.
On 17th January 2021, Aion therapeutics announced the Jamaican-based Aion International Center for Psychedelic Psychiatry opening. It will be specializing in the incorporation of psilocybin in its application in the treatment of:
- Addiction (tobacco, alcohol, and others).
- Depression and anxiety resulting from contracting fatal-illness like HIV and Cancer.
- Drug-Resistant Depression.
The company also has a health and wellness resort meant to treat numerous conditions.
In February 2021, Plant-Based Investment Corp acquired 3,333,333 units from Aion Therapeutic Inc through a non-brokered private placement. Each unit went for $0.075, and PBIC paid a total of $250,000.